Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)

Exclusion Criteria

• •Participant has a history of type 1 diabetes mellitus or a history of ketoacidosis.
• •Participant is losing weight in a weight loss program and is not in the maintenance phase (defined as \<2 kg weight loss in 2 months), or intends to be involved in weight loss intervention outside that prescribed by the study.
• •Participant has a clinically significant hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia).
• •Participant has cirrhosis or active liver disease.
• •Participant has been on dialysis for \< 6 months.
• •Participant has been diagnosed with a significant cardiovascular disorder and has new or worsening signs or symptoms of congestive heart failure within 3 months of signing informed consent.
• •Participant has severe active peripheral vascular disease.
• •Participant has a history of malignancy ≤ 5 years prior to signing informed consent, or \> 5 years without documentation of remission/cure.
• •Participant is under treatment for hyperthyroidism.
• •Participant has a hypersensitivity or contraindication to glipizide.